Rezaei Mahshid, Akhavan Neda, Fathi Fereshteh, Alavi Seyyed Mohammad, Fadaii Mahdiyeh, Dehzad Mohammad Jafar, Askarpour Moein
Nutrition and Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Kinesiology and Nutrition Sciences, School of Integrated Health Sciences, University of Nevada, Las Vegas, NV, USA.
Blood Press. 2025 Dec;34(1):2517122. doi: 10.1080/08037051.2025.2517122. Epub 2025 Jun 12.
Hypertension (HTN) is a leading contributor to cardiovascular disease (CVD). Green tea has been proposed as a natural intervention for blood pressure (BP) management due to its antioxidant content. This study aimed to systematically evaluate the effect of green tea supplementation on systolic (SBP) and diastolic blood pressure (DBP) using a meta-analysis of randomised controlled trials (RCTs).
Eligibility criteria were defined using the PICOS framework. PubMed, Scopus, and Web of Science were searched through January 2024 for randomised controlled trials in adults (≥18 years) comparing green tea supplementation with control or placebo, reporting pre- and post-intervention systolic and diastolic blood pressure (SBP and DBP). Weighted mean differences (WMDs) and 95% confidence intervals (CIs) were pooled using random-effects models. Subgroup analyses and dose-response analyses were performed.
A total of 36 RCTs were included. Green tea reduced SBP (WMD: -1.08 mmHg; 95% CI: -1.98, -0.18; I = 85.0%) and DBP (WMD: -1.09 mmHg; 95% CI: -1.67, -0.50; I = 74.0%). Subgroup analyses showed stronger effects in participants with elevated baseline BP (SBP ≥120 mmHg), those consuming <500 mg/day green tea, studies ≤8 weeks, Asian populations, and women. No clear association was found between BP changes and tea dose or intervention duration.
Green tea supplementation is associated with modest reductions in SBP and DBP. Given the heterogeneity and lack of clear dose-duration effects, green tea is better considered a complementary approach for managing blood pressure.
高血压(HTN)是心血管疾病(CVD)的主要促成因素。由于绿茶含有抗氧化成分,已被提议作为一种控制血压(BP)的天然干预措施。本研究旨在通过对随机对照试验(RCT)的荟萃分析,系统评价补充绿茶对收缩压(SBP)和舒张压(DBP)的影响。
使用PICOS框架定义纳入标准。检索了截至2024年1月的PubMed、Scopus和Web of Science数据库,以查找针对成年人(≥18岁)的随机对照试验,这些试验比较了补充绿茶与对照或安慰剂,并报告了干预前后的收缩压和舒张压(SBP和DBP)。使用随机效应模型汇总加权平均差(WMD)和95%置信区间(CI)。进行了亚组分析和剂量反应分析。
共纳入36项随机对照试验。绿茶降低了收缩压(WMD:-1.08 mmHg;95%CI:-1.98,-0.18;I² = 85.0%)和舒张压(WMD:-1.09 mmHg;95%CI:-1.67,-0.50;I² = 74.0%)。亚组分析显示,在基线血压升高(SBP≥120 mmHg)的参与者、每天饮用绿茶<500 mg的参与者、持续时间≤8周的研究、亚洲人群和女性中,效果更强。未发现血压变化与茶剂量或干预持续时间之间存在明确关联。
补充绿茶与收缩压和舒张压的适度降低有关。鉴于存在异质性且缺乏明确的剂量-持续时间效应,绿茶最好被视为一种辅助控制血压的方法。